ANI Pharmaceuticals, Inc.
ANIP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1,294,169 | $1,312,689 | $1,074,920 |
| - Cash | $262,610 | $217,797 | $149,802 | $144,861 |
| + Debt | $307,392 | $320,078 | $622,822 | $624,092 |
| Enterprise Value | – | $1,396,450 | $1,785,709 | $1,554,151 |
| Revenue | $227,813 | $211,371 | $197,122 | $190,574 |
| % Growth | 7.8% | 7.2% | 3.4% | – |
| Gross Profit | $111,792 | $136,756 | $124,085 | $110,294 |
| % Margin | 49.1% | 64.7% | 62.9% | 57.9% |
| EBITDA | $61,159 | $39,244 | $48,362 | $14,853 |
| % Margin | 26.8% | 18.6% | 24.5% | 7.8% |
| Net Income | $24,134 | $8,549 | $15,681 | -$10,276 |
| % Margin | 10.6% | 4% | 8% | -5.4% |
| EPS Diluted | 1.13 | 0.36 | 0.69 | -0.55 |
| % Growth | 213.9% | -47.8% | 225.5% | – |
| Operating Cash Flow | $44,055 | $75,812 | $34,991 | $15,860 |
| Capital Expenditures | -$6,163 | -$6,909 | -$19,846 | -$2,480 |
| Free Cash Flow | $37,892 | $68,903 | $15,145 | $13,380 |